Clinical trials: Patients with Advanced Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- Trial name
- NCT00004881
- Testing
- MVA-MUC1-IL2 vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Solid Tumor
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
This is a single-center, single-arm clinical study to evaluate the safety, tolerability and preliminary efficacy of [225Ac]Ac-FAPI-XT injection in patients with FAP-positive advanced solid tumors.
- Trial name
- NCT07135128
- Testing
- 225Ac-FAPI-XT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiaorong Sun
Advanced Solid Tumor
A Phase I Trial of Simmitinib in Advanced Solid Tumors
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.
- Trial name
- NCT04058587
- Testing
- Simmitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumor
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an…
- Trial name
- NCT05162755
- Testing
- S095029, S95029 and Sym021
- Where
- 5 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Institut de Recherches Internationales Servier
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
- Trial name
- NCT06777316
- Testing
- CGT4859
- Where
- 13 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Cogent Biosciences, Inc.
Solid Tumor
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension).
- Trial name
- NCT04175847
- Testing
- RC88
- Where
- 4 sites in China
- Volunteers
- 198 people
- Sponsor
- RemeGen Co., Ltd.
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver.
- Trial name
- NCT03468426
- Testing
- BI 836880, Ezabenlimab
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 252 people
- Sponsor
- Boehringer Ingelheim
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390826
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
This is a single-arm, open-label, phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of SY-5933 in patients with KRAS p.G12C mutant advanced solid tumors.
- Trial name
- NCT06006793
- Testing
- SY-5933
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Advanced Malignant Solid Neoplasm
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with…
- Trial name
- NCT01827384
- Testing
- Adavosertib, Carboplatin, Everolimus
- Where
- 8 sites in United States
- Volunteers
- 208 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants…
- Trial name
- NCT01634555
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult, Advanced Solid Tumor
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma
- Trial name
- NCT05868174
- Testing
- 89Zr-TLX250, 177Lu-TLX250 and Peposertib
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Locally Advanced or Metastatic Solid Tumors
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination…
- Trial name
- NCT05012618
- Testing
- LUNA18, Cetuximab
- Where
- 20 sites in United States, Japan
- Volunteers
- 128 people
- Sponsor
- Chugai Pharmaceutical
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Tumors, Lymphoma
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.
- Trial name
- NCT00345189
- Testing
- CNF2024
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Biogen
Tumor Infiltrating Lymphocytes, Safety
A Phase I Study of GC101 TIL in Advanced Solid Tumors
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy
- Trial name
- MIZAR-001 (NCT05417750)
- Testing
- TIL therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Juncell Therapeutics
Neoplasms
A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors
This study will determine the maximum tolerated dose and the dose-limiting toxicities of RO4987655 in patients with advanced and/or metastatic solid tumors.
- Trial name
- NCT00817518
- Testing
- RO4987655
- Where
- 12 sites in France, Germany and 3 more
- Volunteers
- 145 people
- Sponsor
- Hoffmann-La Roche
Malignant Neoplasmas, Solid Tumors
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Treatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer…
- Trial name
- NCT01125891
- Testing
- gemcitabine, ON 01910.Na
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Traws Pharma, Inc.
Neoplasms
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced…
- Trial name
- NCT02760797
- Testing
- Emactuzumab, RO7009789
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer, Pancreatic Cancer
Doxil Topotecan Doublet Cancer Study
The primary objective is to determine the nature and degree of the toxicity of weekly dosing of topotecan in escalating dose levels by cohorts of 3-6 patients in combination with a fixed dose of pegylated liposomal doxorubicin…
- Conditions
- Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT00252889
- Testing
- Topotecan and pegylated doxorubicin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Christiana Care Health Services
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.